Compounds > 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid
Page last updated: 2024-10-21

3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid and Epilepsies, Myoclonic

3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid has been researched along with Epilepsies, Myoclonic in 1 studies

3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid: structure given in first source; NMDA receptor antagonist

Epilepsies, Myoclonic: A clinically diverse group of epilepsy syndromes characterized either by myoclonic seizures or by myoclonus in association with other seizure types. Myoclonic epilepsy syndromes are divided into three subtypes based on etiology: familial, cryptogenic, and symptomatic.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Eriksson, C1
Zou, LP1
Ahlenius, S1
Winblad, B1
Schultzberg, M1

Other Studies

1 other study available for 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid and Epilepsies, Myoclonic

ArticleYear
Inhibition of kainic acid induced expression of interleukin-1 beta and interleukin-1 receptor antagonist mRNA in the rat brain by NMDA receptor antagonists.
    Brain research. Molecular brain research, 2000, Dec-28, Volume: 85, Issue:1-2

    Topics: Animals; Behavior, Animal; Dizocilpine Maleate; Epilepsies, Myoclonic; Excitatory Amino Acid Agonist

2000